within Pharmacolibrary.Drugs.ATC.A;

model A10BD27
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.65,
    Cl             = 0.0003,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg â†’ kg
    adminCount     = 1,
    Vd             = 0.075,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BD27</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>A fixed-dose combination oral antidiabetic medication containing metformin (a biguanide that decreases hepatic glucose production and increases insulin sensitivity), linagliptin (a dipeptidyl peptidase-4 inhibitor enhancing incretin effect), and empagliflozin (a sodium-glucose co-transporter-2 inhibitor promoting urinary glucose excretion). Used in the management of type 2 diabetes mellitus in adults insufficiently controlled on metformin together with at least one of the other components. The combination is approved and marketed under several brands.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic estimates based on standard published values for each component in healthy adults under typical oral dosing. No dedicated peer-reviewed population PK study for the fixed-dose triple combination was located; parameters estimated from individual component data.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BD27;
